[go: up one dir, main page]

MA43342A - Compositions et procédé d'inhibition de cellules souches cancéreuses - Google Patents

Compositions et procédé d'inhibition de cellules souches cancéreuses

Info

Publication number
MA43342A
MA43342A MA43342A MA43342A MA43342A MA 43342 A MA43342 A MA 43342A MA 43342 A MA43342 A MA 43342A MA 43342 A MA43342 A MA 43342A MA 43342 A MA43342 A MA 43342A
Authority
MA
Morocco
Prior art keywords
compositions
stem cells
cancery
inhibition
csc
Prior art date
Application number
MA43342A
Other languages
English (en)
Inventor
Elaine M Hurt
Sotirios Karathanasis
Ralph Minter
Steven Rust
Alan Sandercock
Original Assignee
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Publication date
Publication of MA43342A publication Critical patent/MA43342A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C12N5/0695—Stem cells; Progenitor cells; Precursor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/25—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving enzymes not classifiable in groups C12Q1/26 - C12Q1/66
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)

Abstract

La présente invention concerne généralement des compositions et des procédés utiles dans le traitement du cancer. Plus spécifiquement, les procédés et les compositions peuvent être utilisés pour détecter, quantifier, inhiber, tuer, différencier ou éliminer les cellules souches cancéreuses (csc) et peuvent être utilisés dans le traitement des cancers associés aux csc, en particulier les cancers et les csc qui expriment lox1. .
MA43342A 2015-09-30 Compositions et procédé d'inhibition de cellules souches cancéreuses MA43342A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562235144P 2015-09-30 2015-09-30

Publications (1)

Publication Number Publication Date
MA43342A true MA43342A (fr) 2018-08-08

Family

ID=57121217

Family Applications (1)

Application Number Title Priority Date Filing Date
MA43342A MA43342A (fr) 2015-09-30 Compositions et procédé d'inhibition de cellules souches cancéreuses

Country Status (13)

Country Link
US (2) US11192948B2 (fr)
EP (1) EP3356414A1 (fr)
JP (1) JP6938478B2 (fr)
KR (1) KR20180054818A (fr)
CN (1) CN108290952B (fr)
AU (2) AU2016329409B2 (fr)
CA (1) CA3000285A1 (fr)
HK (2) HK1255053A1 (fr)
IL (1) IL258242B2 (fr)
MA (1) MA43342A (fr)
RU (2) RU2752610C1 (fr)
SG (1) SG10202002926UA (fr)
WO (1) WO2017055511A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11884719B2 (en) * 2018-12-21 2024-01-30 23Andme, Inc. Anti-IL-36 antibodies and methods of use thereof
CN111303280B (zh) * 2020-03-22 2022-01-07 中国人民解放军军事科学院军事医学研究院 高中和活性抗SARS-CoV-2全人源单克隆抗体及应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
AU2003230908A1 (en) 2002-04-11 2003-10-27 Medimmune Vaccines, Inc. Spray freeze dry of compositions for intranasal administration
WO2003087339A2 (fr) 2002-04-11 2003-10-23 Medimmune Vaccines, Inc. Lyophilisation par pulverisation de compositions a administration pulmonaire
EP1494651A4 (fr) 2002-04-11 2010-10-13 Medimmune Vaccines Inc Conservation de matieres bio-actives au moyen de mousse lyophilisee
CN101287449B (zh) 2002-04-11 2010-11-03 米迪缪尼有限公司 喷雾干燥保存生物活性材料
JP4680601B2 (ja) 2002-12-17 2011-05-11 メディミューン・エルエルシー 生物活性材料の高圧噴霧乾燥
JP2006022063A (ja) 2004-07-09 2006-01-26 Univ Nihon Ｌｏｘ−１遺伝子発現抑制剤
CA2715919C (fr) 2007-02-23 2020-04-21 Baylor Research Institute Activation de cellules humaines presentant un antigene par l'intermediaire du recepteur ldl 1 oxyde de type lectine (lox-1) de cellules dendritiques
US20090311271A1 (en) * 2008-05-29 2009-12-17 Wyeth Methods and Compositions for Selective Inhibition of Ligand Binding to the Lectin-Like Receptor for Oxidized Low Density Lipoprotein (LOX-1)
WO2010138171A2 (fr) 2009-05-23 2010-12-02 Incube Labs, Llc Méthodes de traitement du cancer faisant appel à des cellules souches
WO2013119964A2 (fr) 2012-02-08 2013-08-15 Stem Centrx, Inc. Identification et enrichissement de sous-populations cellulaires
US9778264B2 (en) * 2010-09-03 2017-10-03 Abbvie Stemcentrx Llc Identification and enrichment of cell subpopulations
CN103582815A (zh) 2011-02-24 2014-02-12 佛米利昂公司 用于卵巢癌的生物标志物组、诊断方法和测试试剂盒
WO2014028274A1 (fr) 2012-08-15 2014-02-20 California Stem Cell, Inc. Procédé de production rapide de cellules souches cancéreuses de pureté élevée et d'une population de cellules souches cancéreuses de pureté élevée
US9562101B2 (en) * 2013-06-21 2017-02-07 Novartis Ag Lectin-like oxidized LDL receptor 1 antibodies and methods of use
MX2017004103A (es) * 2014-10-01 2017-07-07 Medimmune Ltd Proteinas de union especificas para el receptor 1 de lipoproteinas de baja densidad oxidadas de tipo lectina (lox1) y sus usos.

Also Published As

Publication number Publication date
HK1257189A1 (zh) 2019-10-18
US20220195037A1 (en) 2022-06-23
CN108290952A (zh) 2018-07-17
JP6938478B2 (ja) 2021-09-22
US11192948B2 (en) 2021-12-07
RU2752610C1 (ru) 2021-07-29
SG10202002926UA (en) 2020-05-28
JP2018529716A (ja) 2018-10-11
IL258242B2 (en) 2023-02-01
HK1255053A1 (zh) 2019-08-02
IL258242A (en) 2018-05-31
KR20180054818A (ko) 2018-05-24
US20180273616A1 (en) 2018-09-27
EP3356414A1 (fr) 2018-08-08
AU2020201276B2 (en) 2022-03-17
CA3000285A1 (fr) 2017-04-06
AU2020201276A1 (en) 2020-03-12
IL258242B (en) 2022-10-01
CN108290952B (zh) 2023-05-02
AU2016329409A1 (en) 2018-05-10
RU2021120719A (ru) 2021-11-03
WO2017055511A1 (fr) 2017-04-06
AU2016329409B2 (en) 2019-11-28

Similar Documents

Publication Publication Date Title
EA201891199A1 (ru) Композиции, содержащие бактериальные штаммы
EA201890047A1 (ru) Композиции, содержащие бактериальные штаммы
EA201891201A1 (ru) Композиции, содержащие бактериальные штаммы
EA201891202A1 (ru) Композиции, содержащие бактериальные штаммы
MX2022011546A (es) Composiciones y metodos para el agotamiento de celulas cd137+.
EA201890050A1 (ru) Композиции, содержащие бактериальные штаммы
EA201890049A1 (ru) Композиции, содержащие бактериальные штаммы
EA201890051A1 (ru) Композиции, содержащие бактериальные штаммы
MX2019003623A (es) Composiciones y metodos para el tratamiento de afecciones oftalmicas.
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
MA41013A (fr) Compositions comprenant des souches bactériennes
EA201790446A1 (ru) Цитотоксические бензодиазепиновые производные
MD4685B1 (ro) Metodă de tratament al stărilor asociate cu activarea complementului dependentă de MASP-2
MA40576B1 (fr) Anticorps et immunoconjugués anti-her2
EA201890961A1 (ru) Комбинированная терапия для лечения злокачественных новообразований
MX2019001471A (es) Anticuerpos anti-siglec-7 para el tratamiento del cancer.
MX2016007492A (es) Métodos y composiciones para el tratamiento de afecciones asociadas con el envejecimiento.
MX2018006632A (es) Inhibidores biciclicos de peptidilarginina deiminasa 4 (pad4).
EA201691845A1 (ru) Фармацевтические композиции терапевтически активных соединений
CL2017002774A1 (es) Secuencias de uricasa mejorada y métodos de tratamiento
MX2022007436A (es) Inhibidores de la autotaxina y sus usos.
EA201691844A1 (ru) Фармацевтические композиции терапевтически активных соединений
MX2018012902A (es) Composiciones y métodos para el tratamiento de trastornos de almacenamiento lisosomal y trastornos caracterizados por disfunción lisosomal.
MX2018006700A (es) Inhibidores aza-bencimidazol de peptidilarginina desiminasa (pad4).
EA201991455A1 (ru) Композиции и способы лечения дефицита альфа-1-антитрипсина